Underrecognition of AF Symptom Burden Found to Be Associated With Catheter Ablation Underuse
Atrial fibrillation symptom burden was found to be frequently underrecognized.
Arrhythmia
At-Home Continuous Ambulatory ECG Monitoring Found to Provide Quality Data
A home-based continuous ambulatory ECG monitoring device delivered with at-home instructions was found to be as effective for collecting quality data as in-clinic delivery and monitoring.
Low Iron Storage and Arrhythmogenic Susceptibility in Healthy Women of Childbearing Age
Low iron storage may increase arrhythmogenic susceptibility in healthy women of childbearing age.
Lower Risk for CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Low- vs Standard-Intensity Warfarin Therapy and Thromboembolic Risk in Older Patients With NVAF
Low-intensity warfarin therapy was found to be as effective as standard-intensity I warfarin in lowering the risk for thromboembolism in older patients with nonvalvular atrial fibrillation.
ACC Consensus Decision Pathway for Anticoagulant, Antiplatelet Use in Patients With AF or VTE Scheduled for PCI
Expert consensus decision pathway for anticoagulant and antiplatelet use in patients with atherosclerotic cardiovascular disease or in those with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention.
Early ECMO-Facilitated Resuscitation vs ACLS for OHCA and Refractory Ventricular Fibrillation
In patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation, early extracorporeal membrane oxygenation-facilitated resuscitation was found to improve survival to hospital discharge.
Atrial Fibrillation, Fulminant Myocarditis Observed in Adolescent With COVID-19
Case of a 15-year-old African American girl with COVID-19 who developed atrial fibrillation and fulminant myocarditis.
Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
Edoxaban was found to be superior to placebo for the prevention of stroke and systemic embolism in very elderly Japanese patients with nonvalvular atrial fibrillation.
Rivaroxaban Is Noninferior to Warfarin for AF Patients With a Bioprosthetic Mitral Valve
Investigators examined the effects of rivaroxaban (20 mg once daily) vs dose-adjusted warfarin in patients with atrial fibrillation and a bioprosthetic mitral valve.
-
Loading...
-
Loading...
Next post in Arrhythmia
